Skip to main content
Article thumbnail
Location of Repository

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer

By Neelu Puri and Ravi Salgia
Topics: Original Article
Publisher: Medknow Publications
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
  2. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
  3. A selective small molecule inhibitor of c-Met kinase inhibits c-Metdependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
  4. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
  5. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
  6. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
  7. c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions.
  8. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing.
  9. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.
  10. (1998). Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer
  11. (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene
  12. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.
  13. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy.
  14. (1997). Epidermal growth factor (EGF)-induced generation of hydrogen peroxide: Role in EGF receptor-mediated tyrosine phosphorylation.
  15. (2002). Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol
  16. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
  17. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
  18. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in nonsmall cell lung cancer.
  19. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
  20. Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor.
  21. HGF: A multifunctional growth factor controlling cell scattering.
  22. Inhibitors of epidermal-growthfactor receptors: A review of clinical research with a focus on non-smallcell lung cancer.
  23. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
  24. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
  25. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
  26. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking.
  27. Novel therapies in lung cancer.
  28. (1987). Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem
  29. (2002). Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev
  30. The accuracy of EUS-FNA in assessing mediastinal lymphadenopathy and staging patients with NSCLC.
  31. The EGFR family and its ligands in human cancer: Signaling mechanisms and therapeutic opportunities.
  32. The role of EGFR inhibitors in nonsmall cell lung cancer.
  33. (1998). The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers. Oncol Rep
  34. (1990). tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ
  35. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.
  36. (1992). Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.
  37. (1998). Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
  38. Tyrosine kinase mutations in human cancer.
  39. (1992). Vande Woude GF. Evidence for non-covalent clusters of the c-met protooncogene product.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.